Thirlwell J - Search Results

1

Uncontrolled persistent allergic asthma in practice: eXpeRience registry baseline characteristics.

Braunstahl GJ, Leo J, Thirlwell J, Peachey G, Maykut R. Braunstahl GJ, et al. Among authors: thirlwell j. Curr Med Res Opin. 2011 Apr;27(4):761-7. doi: 10.1185/03007995.2011.557717. Curr Med Res Opin. 2011. PMID: 21405947

2

Omalizumab reduces oral corticosteroid use in patients with severe allergic asthma: real-life data.

Molimard M, Buhl R, Niven R, Le Gros V, Thielen A, Thirlwell J, Maykut R, Peachey G. Molimard M, et al. Among authors: thirlwell j. Respir Med. 2010 Sep;104(9):1381-5. doi: 10.1016/j.rmed.2010.06.001. Respir Med. 2010. PMID: 20599369 Free article.

3

The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics.

Solèr M, Matz J, Townley R, Buhl R, O'Brien J, Fox H, Thirlwell J, Gupta N, Della Cioppa G. Solèr M, et al. Among authors: thirlwell j. Eur Respir J. 2001 Aug;18(2):254-61. doi: 10.1183/09031936.01.00092101. Eur Respir J. 2001. PMID: 11529281 Free article. Clinical Trial.

4

Omalizumab provides long-term control in patients with moderate-to-severe allergic asthma.

Buhl R, Solèr M, Matz J, Townley R, O'Brien J, Noga O, Champain K, Fox H, Thirlwell J, Della Cioppa G. Buhl R, et al. Among authors: thirlwell j. Eur Respir J. 2002 Jul;20(1):73-8. doi: 10.1183/09031936.02.00278102. Eur Respir J. 2002. PMID: 12166585 Free article. Clinical Trial.

5

The anti-IgE antibody omalizumab improves asthma-related quality of life in patients with allergic asthma.

Buhl R, Hanf G, Solèr M, Bensch G, Wolfe J, Everhard F, Champain K, Fox H, Thirlwell J. Buhl R, et al. Among authors: thirlwell j. Eur Respir J. 2002 Nov;20(5):1088-94. doi: 10.1183/09031936.02.00016502. Eur Respir J. 2002. PMID: 12449159 Free article. Clinical Trial.

6

Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma.

Holgate ST, Chuchalin AG, Hébert J, Lötvall J, Persson GB, Chung KF, Bousquet J, Kerstjens HA, Fox H, Thirlwell J, Cioppa GD; Omalizumab 011 International Study Group. Holgate ST, et al. Among authors: thirlwell j. Clin Exp Allergy. 2004 Apr;34(4):632-8. doi: 10.1111/j.1365-2222.2004.1916.x. Clin Exp Allergy. 2004. PMID: 15080818 Clinical Trial.

7

Recombinant humanized mAb-E25, an anti-IgE mAb, in birch pollen-induced seasonal allergic rhinitis.

Adelroth E, Rak S, Haahtela T, Aasand G, Rosenhall L, Zetterstrom O, Byrne A, Champain K, Thirlwell J, Cioppa GD, Sandström T. Adelroth E, et al. Among authors: thirlwell j. J Allergy Clin Immunol. 2000 Aug;106(2):253-9. doi: 10.1067/mai.2000.108310. J Allergy Clin Immunol. 2000. PMID: 10932067 Clinical Trial.

8

Formoterol mono- and combination therapy with tiotropium in patients with COPD: a 6-month study.

Vogelmeier C, Kardos P, Harari S, Gans SJ, Stenglein S, Thirlwell J. Vogelmeier C, et al. Among authors: thirlwell j. Respir Med. 2008 Nov;102(11):1511-20. doi: 10.1016/j.rmed.2008.07.020. Epub 2008 Sep 19. Respir Med. 2008. PMID: 18804362 Free article. Clinical Trial.

9

Effects of formoterol on exercise tolerance in severely disabled patients with COPD.

Neder JA, Fuld JP, Overend T, Thirlwell J, Carter R, Stevenson R, Ward SA. Neder JA, et al. Among authors: thirlwell j. Respir Med. 2007 Oct;101(10):2056-64. doi: 10.1016/j.rmed.2007.06.006. Epub 2007 Jul 19. Respir Med. 2007. PMID: 17658249 Free article. Clinical Trial.

10

Robertson JFR, Cheung KL, Noguchi S, Shao Z, Degboe A, Lichfield J, Thirlwell J, Fazal M, Ellis MJ. Robertson JFR, et al. Among authors: thirlwell j. Eur J Cancer. 2018 May;94:206-215. doi: 10.1016/j.ejca.2018.02.026. Epub 2018 Mar 22. Eur J Cancer. 2018. PMID: 29574365 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

18 results

Search Page